Lobby organisation
BioMarin UK Limited
Business / industry · Health & pharma · HQ: United Kingdom · Transparency Register entry
As of 9 September 2026, BioMarin UK Limited appears in 10 declared MEP meetings (10 different MEPs), most often with European People's Party.
In their own words
“BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. Our therapy portfolio consists of several commercialised products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BioMarin.com”
Stated goals from the organisation's own Transparency Register filing.
Who they meet, and when
Which groups they meet
Share of this organisation's 10 declared meetings, by the meeting MEP's political group.
Meetings by year
Declared meetings per calendar year, 2022–2026. Bar length is relative to its busiest year (5 in 2024).
Group is each MEP's current political group, not necessarily the one they sat with at the time. Shares are rounded to whole percent.
The MEPs they meet most
The 10 most recent declared meetings
| Date | MEP | Subject |
|---|---|---|
| 16 Apr 2026 | Stine Bosse | Biotech Act |
| 4 Feb 2025 | Michael McNamara | Technologies developed for rare diseases |
| 17 Oct 2024 | András Tivadar Kulja | EU biotechnology |
| 15 Oct 2024 | Francesco Torselli | Incontro conoscitivo per discutere delle nuove proposte regolatorie in tema di salute e malattie rare |
| 8 Oct 2024 | Dolors Montserrat | New EU Pharmaceutical Legislation |
| 25 Sep 2024 | Billy Kelleher | EU Health Policy |
| 30 Jan 2024 | Nicolás González Casares | Pharma legislation |
| 7 Jun 2023 | Tiemo Wölken | Revision of Pharmaceutical Legislation (staff level) |
| 30 Jan 2023 | Sirpa Pietikäinen | EU’s action in the field of rare diseases |
| 8 Nov 2022 | Susana Solís Pérez | EHDS |
Meeting an MEP is a normal part of democratic life; the record is shown so anyone can see it.